Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study


      • Baseline QOL scores may predict survival in ovarian cancer patients.
      • Identifying mechanisms to improve QOL for ovarian cancer patients may result in better outcomes.
      • Serial improving QOL may predict improved patient outcomes.



      Evaluate association between baseline quality of life (QOL) and changes in QOL measured by FACT-O TOI with progression-free disease (PFS) and overall survival (OS) in advanced epithelial ovarian cancer (EOC).


      Patients enrolled in GOG-0218 with completed FACT-O TOI assessments at baseline and at least one follow-up assessment were eligible. Baseline FACT-O TOI scores were sorted by quartiles (Q1-4) and outcomes compared between Q1 and Q2-4 with log-rank statistic and multivariate Cox regression adjusting for age, stage, post-surgical residual disease size, and performance status (PS). Trends in FACT-O TOI scores from baseline to the latest follow-up assessment were evaluated for impact on intragroup (Q1 or Q2-4) outcome by log-rank analysis.


      Of 1152 eligible patients, 283 formed Q1 and 869 formed Q2-4. Mean baseline FACT-O TOI scores were 47.5 for Q1 vs. 74.7 for Q2-4 (P < 0.001). Q1 compared to Q2-4 had worse median OS (37.5 vs. 45.6 months, P = 0.001) and worse median PFS (12.5 vs. 13.1 months, P = 0.096). Q2-4 patients had decreased risks of disease progression (HR 0.974, 95% CI 0.953–0.995, P = 0.018), and death (HR 0.963, 95% CI 0.939–0.987, P = 0.003) for each five-point increase in baseline FACT-O TOI. Improving versus worsening trends in FACT-O TOI scores were associated with longer median PFS (Q1: 12.7 vs. 8.6 months, P = 0.001; Q2-4: 16.7 vs. 11.1 months, P < 0.001) and median OS (Q1: 40.8 vs. 16 months, P < 0.001; Q2-4: 54.4 vs. 33.6 months, P < 0.001).


      Baseline FACT-O TOI scores were independently prognostic of PFS and OS while improving compared to worsening QOL was associated with significantly better PFS and OS in women with EOC.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2015.
        CA Cancer J. Clin. 2015; 65: 5-29
        • Aletti G.D.
        • Dowdy S.C.
        • Gostout B.S.
        • et al.
        Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.
        Obstet. Gynecol. 2006; 107: 77-85
        • Bristow R.E.
        • Tomacruz R.S.
        • Armstrong D.K.
        • et al.
        Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
        J. Clin. Oncol. 2002; 20: 1248-1259
        • Chi D.S.
        • Eisenhauer E.L.
        • Lang J.
        • et al.
        What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?.
        Gynecol. Oncol. 2006; 103: 559-564
        • Jelovac D.
        • Armstrong D.K.
        Recent progress in the diagnosis and treatment of ovarian cancer.
        CA Cancer J. Clin. 2011; 61: 183-203
        • Winter 3rd, W.E.
        • Maxwell G.L.
        • Tian C.
        • et al.
        Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a gynecologic oncology group study.
        J. Clin. Oncol. 2008; 26: 83-89
        • Katsumata N.
        • Yasuda M.
        • Takahashi F.
        • et al.
        Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
        Lancet. 2009; 374: 1331-1338
        • Armstrong D.K.
        • Bundy B.
        • Wenzel L.
        • et al.
        Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
        N. Engl. J. Med. 2006; 354: 34-43
        • Bookman M.A.
        • Brady M.F.
        • McGuire W.P.
        • et al.
        Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup.
        J. Clin. Oncol. 2009; 27: 1419-1425
        • Burger R.A.
        • Brady M.F.
        • Bookman M.A.
        • et al.
        Incorporation of bevacizumab in the primary treatment of ovarian cancer.
        N. Engl. J. Med. 2011; 365: 2473-2483
        • Herzog T.J.
        • Armstrong D.K.
        • Brady M.F.
        • et al.
        Ovarian cancer clinical trial endpoints: society of gynecologic oncology white paper.
        Gynecol. Oncol. 2014; 132: 8-17
        • Coons S.J.
        • Kaplan R.M.
        Assessing health-related quality of life: application to drug therapy.
        Clin. Ther. 1992; 14 (discussion 849): 850-858
        • von Gruenigen V.E.
        • Huang H.Q.
        • Gil K.M.
        • et al.
        The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a gynecologic oncology group study.
        Gynecol. Oncol. 2012; 124: 379-382
        • Wenzel L.
        • Huang H.Q.
        • Monk B.J.
        • et al.
        Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a gynecologic oncology group study.
        J. Clin. Oncol. 2005; 23: 5605-5612
        • Djarv T.
        • Metcalfe C.
        • Avery K.N.
        • et al.
        Prognostic value of changes in health-related quality of life scores during curative treatment for esophagogastric cancer.
        J. Clin. Oncol. 2010; 28: 1666-1670
        • Ediebah D.E.
        • Coens C.
        • Zikos E.
        • et al.
        Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial.
        Br. J. Cancer. 2014; 110: 2427-2433
        • Sadetsky N.
        • Hubbard A.
        • Carroll P.R.
        • Satariano W.
        Predictive value of serial measurements of quality of life on all-cause mortality in prostate cancer patients: data from CaPSURE (cancer of the prostate strategic urologic research endeavor) database.
        Qual. Life Res. 2009; 18: 1019-1027
        • Monk B.J.
        • Huang H.Q.
        • Burger R.A.
        • et al.
        Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a gynecologic oncology group study.
        Gynecol. Oncol. 2013; 128: 573-578
        • Basen-Engquist K.
        • Bodurka-Bevers D.
        • Fitzgerald M.A.
        • et al.
        Reliability and validity of the functional assessment of cancer therapy-ovarian.
        J. Clin. Oncol. 2001; 19: 1809-1817
        • Gotay C.C.
        • Kawamoto C.T.
        • Bottomley A.
        • Efficace F.
        The prognostic significance of patient-reported outcomes in cancer clinical trials.
        J. Clin. Oncol. 2008; 26: 1355-1363
        • Winter 3rd, W.E.
        • Maxwell G.L.
        • Tian C.
        • et al.
        Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study.
        J. Clin. Oncol. 2007; 25: 3621-3627